Program
emraclidine
Also written as “Emraclidine”, “CVL-231” and “Emraclidine 30 mg”.
In AbbVie’s pipeline, M4 PAM
. Its studies are mostly in Schizophrenia · Alzheimer Disease · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 172 open or running | phase 2since Jan 27, 2022 | Oct 16, 2019 | Dec 2026phase 1 · NCT07219030 |
| Pfizer | 10 open or running | phase 1since Jul 6, 2017 | Jul 6, 2017 | none ahead |
- Named in AbbVie’s own pipeline as
Emraclidine
, phase 2, as of Jul 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jul 6, 2017.
- Oct 16, 2019AbbVie’s first study: phase 1 study in SchizophreniaNew to AbbVieAbbVie · NCT04136873 · 130 enrolled · United States
- Feb 1, 2021Phase 1 study in SchizophreniaAbbVie · NCT04787302 · 15 enrolled · United States, Belgium
- Jul 28, 2021Named emraclidineINNProposed as its International Nonproprietary Name in WHO's List 125 · before, CVL-231
- Nov 1, 2021Phase 1 study in SchizophreniaAbbVie · NCT05106309 · 16 enrolled · United States
- Jan 27, 2022Phase 1 study in SchizophreniaAbbVie · NCT05245539 · 151 enrolled · United States
- Jan 27, 20222 phase 2 studies in SchizophreniaAbbVie · NCT05227703, NCT05227690
- Jun 29, 2022Phase 2 study in SchizophreniaAbbVie · NCT05443724 · 698 enrolled · United States, Bulgaria, Hungary and more
- Dec 1, 2022Phase 1 study in Healthy ParticipantsAbbVie · NCT05644977 · 17 enrolled · United States
- Jun 13, 20233 phase 1 studiesAbbVie · NCT05915546, NCT05933187, NCT05935033
- Jul 2, 2023Phase 1 study in Renal InsufficiencyAbbVie · NCT05940402 · 58 enrolled · United States
- Mar 1, 2024Phase 1 study in Healthy ParticipantsAbbVie · NCT06301971 · 8 enrolled · United States
- Apr 11, 2024Phase 1 study in Healthy ParticipantsAbbVie · NCT06366243 · 20 enrolled · United States
- Aug 22, 2025Phase 2 study in SchizophreniaAbbVie · NCT07145918 · 268 planned · United States
- Oct 17, 2025Phase 1 study in Healthy VolunteerAbbVie · NCT07219030 · 52 planned · United States
- May 8, 2026Phase 1 study in Healthy VolunteersAbbVie · NCT07587008 · 12 enrolled · United States
Ahead
- Dec 2026Primary completion: phase 1 study in Healthy VolunteerAbbVie · NCT07219030
- Feb 2028Primary completion: phase 2 study in SchizophreniaAbbVie · NCT07145918
TargetBeta
“M4 PAM”the company's pipeline, read by Claude · source
Other programs on CHRM4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
| xanomelinerule | Bristol-Myers Squibb | phase 4 | 38 |
| GXV-813 | Novartis | phase 2 | 1 |
| ABBV-1042 | AbbVie | phase 1 | 1 |
| BMS-986521 | Bristol-Myers Squibb | phase 1 | 1 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07587008Healthy Volunteers · United States | 1 | Completed | AbbVie | Jul 17, 2026 | 12 |
| NCT07219030Healthy Volunteer · United States | 1 | Recruiting | AbbVie | Dec 2026 | 52 |
| NCT07145918Schizophrenia · United States | 2 | Recruiting | AbbVie | Feb 2028 | 268 |
| NCT06366243Healthy Participants · United States | 1 | Completed | AbbVie | Jun 20, 2024 | 20 |
| NCT06301971Healthy Participants · United States | 1 | Completed | AbbVie | Apr 4, 2024 | 8 |
| NCT05940402Renal Insufficiency · United States | 1 | Completed | AbbVie | Dec 19, 2024 | 58 |
| NCT05935033Hepatic Impairment · United States | 1 | Completed | AbbVie | Feb 21, 2025 | 38 |
| NCT05933187Healthy Participants · United States | 1 | Completed | AbbVie | Sep 12, 2023 | 15 |
| NCT05915546Healthy · United States | 1 | Completed | AbbVie | Jul 26, 2023 | 16 |
| NCT05644977Healthy Participants · United States | 1 | Completed | AbbVie | Apr 14, 2025 | 17 |
| NCT05443724Schizophrenia · United States, Bulgaria, Hungary and more | 2 | Terminated | AbbVie | Jun 25, 2025 | 698 |
| NCT05245539Schizophrenia · United States | 1 | Completed | AbbVie | Oct 19, 2022 | 151 |
| NCT05227703Schizophrenia · United States, Bulgaria, Hungary | 2 | Completed | AbbVie | Aug 15, 2024 | 391 |
| NCT05227690Schizophrenia · United States, Bulgaria | 2 | Completed | AbbVie | Aug 23, 2024 | 385 |
| NCT05106309Schizophrenia · United States | 1 | Completed | AbbVie | Feb 24, 2022 | 16 |
| NCT04787302Schizophrenia · United States, Belgium | 1 | Completed | AbbVie | Jul 14, 2023 | 15 |
| NCT04136873Schizophrenia · United States | 1 | Completed | AbbVie | May 7, 2021 | 130 |
| NCT03217604Healthy Volunteers · Belgium | 1 | Completed | Pfizer | Feb 1, 2018 | 17 |
How it is read
Names in the registry
- “Emraclidine”, 9 entries
- “CVL-231”, 5 entries
- “Emraclidine 30 mg”, 3 entries
- “Emraclidine 15 mg”, 1 entry
- “Emraclidine 10 mg”, 1 entry
Codes read as this program: CVL231.
Conditions, from the studies’ own filings
- Schizophrenia, 8 studies
- Alzheimer Disease, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.